Teriflunomide Use for MS in GCC Countries
Published on Wed, 9 Mar 2022
Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative review
With rising MS prevalence in GCC countries, experts convened to review real-world data on teriflunomide’s role in managing relapsing-remitting MS (RRMS). They recommend teriflunomide for patients aged 18+ with clinically isolated syndrome or RRMS, emphasizing cost-effectiveness, adherence, and safety. The consensus also considers cultural factors, monitoring requirements, and COVID-19 implications. This evidence-based guidance aims to support clinicians in daily practice, improving patient outcomes through tailored MS management strategies.